NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity RFA-DK-22-039 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) seeks to support multidisciplinary research teams with complementary expertise in HIV and pathobiology, pathophysiology, and/or metabolism in organs, tissues, and/or biological systems of specific interest to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). These teams will comprehensively interrogate fundamental biological mechanisms underlying HIV-associated comorbidities, co-infections, and complications relevant to the mission of the NIDDK and advance progress toward preventing or alleviating them.
Notice NOT-HL-22-054 from the NIH Guide for Grants and Contracts
Notice NOT-HD-22-051 from the NIH Guide for Grants and Contracts
Notice NOT-CA-23-008 from the NIH Guide for Grants and Contracts
Notice NOT-OD-23-010 from the NIH Guide for Grants and Contracts
Notice NOT-HD-22-050 from the NIH Guide for Grants and Contracts
Notice NOT-HD-22-053 from the NIH Guide for Grants and Contracts
Notice NOT-CA-22-140 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-23-021 from the NIH Guide for Grants and Contracts. Avenir means future in French, and this award looks toward the future by supporting early stage investigators proposing highly innovative studies. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field. NIDA has developed two Avenir Award Programs, one for HIV/AIDS research and the other for genetics or epigenetics studies.
Notice NOT-CA-22-137 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DA-24-007 from the NIH Guide for Grants and Contracts. oThe goal of this FOA is to attract outstanding early-stage investigators to the field of chemistry and pharmacology of substance used disorders. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field. In recent years, there have been significant advances in methods and technologies for the identification of novel targets, mechanisms, and pathways of interest to substance use disorders and in identification of probes and optimized compounds for developing novel therapeutic agents. This FOA is to enable investigators with knowledge in the emerging chemical, pharmacological, and drug discovery technologies to pursue innovative and transformative research on chemical and pharmacological aspects of substance use disorders.
Notice NOT-GM-23-007 from the NIH Guide for Grants and Contracts
Notice NOT-DA-22-084 from the NIH Guide for Grants and Contracts
Notice NOT-HS-23-001 from the NIH Guide for Grants and Contracts
Notice NOT-DE-22-020 from the NIH Guide for Grants and Contracts
Notice NOT-CA-23-003 from the NIH Guide for Grants and Contracts
Notice NOT-GM-23-006 from the NIH Guide for Grants and Contracts
Notice NOT-DE-23-001 from the NIH Guide for Grants and Contracts
Notice NOT-AG-22-044 from the NIH Guide for Grants and Contracts
Notice NOT-CA-23-007 from the NIH Guide for Grants and Contracts